ETFs Seelos Therapeutics, Inc.

SEELQ

US81577F4063

Biotechnology & Medical Research

Market Closed - OTC Markets 12:36:37 29/10/2026 am IST			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	-

29/12	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
21/25/21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI

ETFs positioned on Seelos Therapeutics, Inc.

Name		YTD change	Weight	AuM
VANGUARD ALL-EQUITY ETF PORTFOLIO - CAD		+15.36%	0%	12,086 M€

Seelos Therapeutics, Inc. has ongoing preclinical programs, including SLS-004, SLS-006, and SLS-007. It has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.

Employees

Sector

Biotechnology & Medical Research

More about the company